Neurodegenerative Diseases

Mini Reviews

APP Processing and the APP-KPI Domain Involvement in the Amyloid Cascade

Menéndez-González M. · Pérez-Pinera P. · Martínez-Rivera M. · Calatayud M.T. · Blázquez Menes B.

Author affiliations

Neurology Department, Hospital Universitario Central de Asturias, Oviedo, Spain

Keywords: Kunitz protease inhibitorAmyloid beta precursor proteinNerve growth factorLipoprotein receptor-related proteinTumor necrosis factor-alpha-converting enzymeNotch1

Related Articles for ""
Neurodegenerative Dis 2005;2:277–283
https://doi.org/10.1159/000092315

Log in to MyKarger to check if you already have access to this content.


Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve

  • Unlimited fulltext viewing Of this article
  • Organize, annotate And mark up articles
  • Printing And downloading restrictions apply

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Mini Reviews

Received: September 14, 2005
Accepted: December 08, 2005
Published online: May 05, 2006
Issue release date: May 2006

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: https://www.karger.com/NDD

Abstract

Alternative APP mRNA splicing can generate isoforms of APP containing a Kunitz protease inhibitor (KPI) domain. KPI is one of the main serine protease inhibitors. Protein and mRNA KPI(+)APP levels are elevated in Alzheimer’s disease (AD) brain and are associated with increased amyloid beta deposition. In the last years increasing evidence on multiple points in the amyloid cascade where KPI(+)APP is involved has been accumulated, admitting an outstanding position in the pathogenesis of AD to the KPI domain. This review focuses on the APP processing, the molecular activity of KPI and its physiological and pathological roles and the KPI involvement in the amyloid cascade through the nerve growth factor, the lipoprotein receptor-related protein, the tumor necrosis factor-alpha converting enzyme and the Notch1 protein.

© 2005 S. Karger AG, Basel



Related Articles:

References

  1. Collin RW, van den Hurk WH, Martens GJ: Biosynthesis and differential processing of two pools of amyloid-beta precursor protein in a physiologically inducible neuroendocrine cell. J Neurochem 2005;94:1015–1024.
    External Resources
  2. Georgopoulou N, McLaughlin M, McFarlane I, Breen KC: The role of post-translational modification in beta-amyloid precursor protein processing. Biochem Soc Symp 2001;67:23–36.
    External Resources
  3. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, McClure D, Ward PJ: Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990;248:1122–1124.
    External Resources
  4. Selkoe DJ: Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer’s disease. Annu Rev Cell Biol 1994;10:373–403.
    External Resources
  5. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K: Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. Cell 1989;7:115–126.
    External Resources
  6. Vingtdeux V, Hamdane M, Gompel M, Begard S, Drobecq H, Ghestem A, Grosjean ME, Kostanjevecki V, Grognet P, Vanmechelen E, Buee L, Delacourte A, Sergeant N: Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis 2005;in press.
  7. Pietrzik CU, Hoffmann J, Stober K, Chen CY, Bauer C, Otero DA, Roch JM, Herzog V: From differentiation to proliferation: the secretory amyloid precursor protein as a local mediator of growth in thyroid epithelial cells. Proc Natl Acad Sci USA 1998;17;95:1770–1775.
    External Resources
  8. Caille I, Allinquant B, Dupont E, Bouillot C, Langer A, Muller U, Prochiantz A: Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. Development 2004;131:2173–2181.
    External Resources
  9. Wang R, Zhang JY, Yang F, Ji ZJ, Chakraborty G, Sheng SL: A novel neurotrophic peptide: APP63–73. Neuroreport 2004;15:2677–2680.
    External Resources
  10. Bour A, Little S, Dodart JC, Kelche C, Mathis C: A secreted form of the beta-amyloid precursor protein (sAPP695) improves spatial recognition memory in OF1 mice. Neurobiol Learn Mem 2004;81:27–38.
    External Resources
  11. Sennvik K, Bogdanovic N, Volkmann I, Fastbom J, Benedikz E: Beta-secretase-cleaved amyloid precursor protein in Alzheimer brain: a morphologic study. J Cell Mol Med 2004;8:127–134.
    External Resources
  12. Oltersdorf T, Fritz LC, Schenk DB, Lieberburg I, Johnson-Wood KL, Beattie EC, Ward PJ, Blacher RW, Dovey HF, Sinha S: The secreted form of the Alzheimer’s amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 1989;341:144–147.
    External Resources
  13. Van Nostrand WE, Farrow JS, Wagner SL, Bhasin R, Goldgaber D, Cotman CW, Cunningham DD: The predominant form of the amyloid beta-protein precursor in human brain is protease nexin 2. Proc Natl Acad Sci USA 1991;88:10302–10306.
    External Resources
  14. Van Nostrand WE, Wagner SL, Suzuki M, Choi BH, Farrow JS, Geddes JW, Cotman CW, Cunningham DD: Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature 1989;341:546–549.
    External Resources
  15. LeBlanc AC, Chen HY, Autilio-Gambetti L, Gambetti P: Differential APP gene expression in rat cerebral cortex, meninges, and primary astroglial, microglial and neuronal cultures. FEBS Lett 1991;292:171–178.
    External Resources
  16. Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin LH, Selkoe DJ, Younkin SG: The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci USA 1989;86:6338–6342.
    External Resources
  17. Sandbrink R, Masters CL, Beyreuther K: APP gene family: unique age-associated changes in splicing of Alzheimer’s betaA4-amyloid protein precursor. Neurobiol Dis 1994;1:13–24.
    External Resources
  18. Oltersdorf T, Fritz LC, Schenk DB, Lieberburg I, Johnson-Wood KL, Beattie EC, Ward PJ, Blacher RW, Dovey HF, Sinha S: The secreted form of the Alzheimer’s amyloid precursor protein with the Kunitz domain is protease nexin-II. Nature 1989;341:144–147.
    External Resources
  19. Kido H, Fukutomi A, Schilling J, Wang Y, Cordell B, Katunuma N: Protease-specificity of Kunitz inhibitor domain of Alzheimer’s disease amyloid protein precursor. Biochem Biophys Res Commun 1990;167:716–721.
    External Resources
  20. Godfroid E, Octave JN: Glycosylation of the amyloid peptide precursor containing the Kunitz protease inhibitor domain improves the inhibition of trypsin. Biochem Biophys Res Commun 1990;171:1015–1021.
    External Resources
  21. Saito F, Yanagisawa K, Miyatake T: Soluble derivatives of beta/A4 amyloid protein precursor in human cerebrospinal fluid are both N- and O-glycosylated. Brain Res Mol Brain Res 1993;19:171–174.
    External Resources
  22. Hook VY, Sei C, Yasothornsrikul S, Toneff T, Kang YH, Efthimiopoulos S, Robakis NK, Van Nostrand W: The Kunitz protease inhibitor form of the amyloid precursor protein (KPI/APP) inhibits the proneuropeptide processing enzyme prohormone thiol protease (PTP): colocalization of KPI/APP and PTP in secretory vesicles. J Biol Chem 1999;274:3165–3172.
    External Resources
  23. Oyama F, Hashino K, Oyama R, Kato I, Titani K: Improved method for expression of Kunitz-type serine proteinase inhibitor domain of beta-amyloid protein precursor in Escherichia coli and characterization of disulfide bonds of the product. J Biochem (Tokyo) 1993;114:813–819.
    External Resources
  24. Moya KL, Confaloni AM, Allinquant B: In vivo neuronal synthesis and axonal transport of Kunitz protease inhibitor (KPI)-containing forms of the amyloid precursor protein. J Neurochem 1994;63:1971–1974.
    External Resources
  25. Conboy L, Murphy KJ, Regan CM: Amyloid precursor protein expression in the rat hippocampal dentate gyrus modulates during memory consolidation. J Neurochem 2005;in press.
  26. Palmert MR, Podlisny MB, Golde TE, Cohen ML, Kovacs DM, Tanzi RE, Gusella JF, Whitehouse PJ, Witker DS, Oltersdorf T, et al: The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives. Prog Clin Biol Res 1989;317:971–984.
    External Resources
  27. Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D: Kunitz protease inhibitor-containing amyloid beta protein precursor immunoreactivity in Alzheimer’s disease. J Neuropathol Exp Neurol 1992;51:76–83.
    External Resources
  28. Moir RD, Lynch T, Bush AI, Whyte S, Henry A, Portbury S, Multhaup G, Small DH, Tanzi RE, Beyreuther K, Masters CL: Relative increase in Alzheimer’s disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J Biol Chem 1998;273:5013–5019.
    External Resources
  29. Urakami K, Takahashi K, Saito H, Okada A, Nakamura S, Tanaka S, Kitaguchi N, Tokushima Y, Yamamoto S: Amyloid beta protein precursors with Kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type. Acta Neurol Scand 1992;85:343–346.
    External Resources
  30. Zhan SS, Sandbrink R, Beyreuther K, Schmitt HP: APP with Kunitz type protease inhibitor domain (KPI) correlates with neuritic plaque density but not with cortical synaptophysin immunoreactivity in Alzheimer’s disease and non-demented aged subjects: a multifactorial analysis. Clin Neuropathol 1995;14:142–149.
    External Resources
  31. Willoughby DA, Rozovsky I, Lo AC, Finch CE: Beta-amyloid precursor protein (APP) and APP-RNA are rapidly affected by glutamate in cultured neurons: selective increase of mRNAs encoding a Kunitz protease inhibitor domain. J Mol Neurosci 1995;6:257–276.
    External Resources
  32. Lesne S, Ali C, Gabriel C, Croci N, MacKenzie ET, Glabe CG, Plotkine M, Marchand-Verrecchia C, Vivien D, Buisson A: NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci 2005;25:9367–9377.
    External Resources
  33. Suzuki A, Takashima S, Mizuguchi M, Kato M, Kunishita T, Tabira T: High expression on Kunitz-type protease inhibitor-containing substances in the cerebral vessels of patients with Down syndrome. Tohoku J Exp Med 1994;174:181–187.
    External Resources
  34. Beyer K, Lao JI, Carrato C, Mate JL, Lopez D, Ferrer I, Ariza A: Upregulation of amyloid precursor protein isoforms containing Kunitz protease inhibitor in dementia with Lewy bodies. Brain Res Mol Brain Res 2004;131:131–135.
    External Resources
  35. Barrachina M, Dalfo E, Puig B, Vidal N, Freixes M, Castano E, Ferrer I: Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor. Neurochem Int 2005;46:253–260.
    External Resources
  36. Refolo LM, Salton SR, Anderson JP, Mehta P, Robakis NK: Nerve and epidermal growth factors induce the release of the Alzheimer amyloid precursor from PC 12 cell cultures. Biochem Biophys Res Commun 1989;164:664–670.
    External Resources
  37. Wion D, Le Bert M, Brachet P: Messenger RNAs of beta-amyloid precursor protein and prion protein are regulated by nerve growth factor in PC12 cells. Int J Dev Neurosci 1988;6:387–393.
    External Resources
  38. Perry EK: Nerve growth factor and the basal forebrain cholinergic system: a link in the etiopathology of neurodegenerative dementias? Alzheimer Dis Assoc Disord 1990;4:1–13.
    External Resources
  39. Salehi A, Delcroix JD, Swaab DF: Alzheimer’s disease and NGF signaling. J Neural Transm 2004;111:323–345.
    External Resources
  40. Castro M, Marks CB, Nilsson B, Anderson S: Does the Kunitz domain from the Alzheimer’s amyloid beta protein precursor inhibit a kallikrein responsible for post-translational processing of nerve growth factor precursor? FEBS Lett 1990;267:207–212.
    External Resources
  41. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hshieh TT, Ranganathan S, Battey FD, Liu CX, Bacskai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT: The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem 2005;280:17777–17785.
    External Resources
  42. Lleo A, Waldron E, von Arnim CA, Herl L, Tangredi MM, Peltan ID, Strickland DK, Koo EH, Hyman BT, Pietrzik CU, Berezovska O: Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for {gamma}-secretase. J Biol Chem 2005;280:27303–27309.
    External Resources
  43. Yoon IS, Pietrzik CU, Kang DE, Koo EH: Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-secretase pathway without altering amyloid precursor protein/LRP nuclear signaling. J Biol Chem 2005;280:20140–20147.
    External Resources
  44. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH: FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. J Neurosci 2004;24:4259–4265.
    External Resources
  45. Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT: Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. J Neurosci 2001;21:8354–8361.
    External Resources
  46. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH: The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 2002;21:5691–5700.
    External Resources
  47. Sanchez L, Alvarez V, Gonzalez P, Gonzalez I, Alvarez R, Coto E: Variation in the LRP-associated protein gene (LRPAP1) is associated with late-onset Alzheimer disease. Am J Med Genet 2001;105:76–78.
    External Resources
  48. Ma SL, Ng HK, Baum L, Pang JC, Chiu HF, Woo J, Tang NL, Lam LC: Low-density lipoprotein receptor-related protein 8 (apolipoprotein E receptor 2) gene polymorphisms in Alzheimer’s disease. Neurosci Lett 2002;332:216–218.
    External Resources
  49. Kolsch H, Ptok U, Mohamed I, Schmitz S, Rao ML, Maier W, Heun R: Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer’s disease. Am J Med Genet [B] 2003;121:128–130.
    External Resources
  50. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic B: Clearance of Alzheimer’s amyloid-β1–40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489–1499.
    External Resources
  51. Moir RD, Tanzi RE: LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr Alzheimer Res 2005;2:269–273.
    External Resources
  52. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G: The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. J Biol Chem 2004;279:29639–29646.
    External Resources
  53. Rebeck GW, Moir RD, Mui S, Strickland DK, Tanzi RE, Hyman BT: Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. Brain Res Mol Brain Res 2001;87:238–245.
    External Resources
  54. Santiago-Garcia J, Mas-Oliva J, Innerarity TL, Pitas RE: Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J Biol Chem 2001;276:30655–30661.
    External Resources
  55. Goto JJ, Tanzi RE: The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer’s A beta generation: development of a cell-based model system. J Mol Neurosci 2002;19:37–41.
    External Resources
  56. Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA: Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765–27767.
    External Resources
  57. Slack BE, Ma LK, Seah CC: Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumor necrosis factor-alpha converting enzyme. Biochem J 2001;357:787–794.
    External Resources
  58. Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F: Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. FEBS J 2005;272:5808–5820.
    External Resources
  59. Villanueva de la Torre T, Bech-Serra JJ, Ruiz-Paz S, Baselga J, Arribas J: Inactivating mutations block the tumor necrosis factor-alpha-converting enzyme in the early secretory pathway. Biochem Biophys Res Commun 2004;314:1028–1035.
    External Resources
  60. Allinson TM, Parkin ET, Condon TP, Schwager SL, Sturrock ED, Turner AJ, Hooper NM: The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur J Biochem 2004;271:2539–2547.
    External Resources
  61. Tarassishin L, Yin YI, Bassit B, Li YM: Processing of Notch and amyloid precursor protein by gamma-secretase is spatially distinct. Proc Natl Acad Sci USA 2004;101:17050–17055.
    External Resources
  62. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G: Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem 2005;280:25892–25900.
    External Resources
  63. Blat Y, Meredith JE, Wang Q, Bradley JD, Thompson LA, Olson RE, Stern AM, Seiffert D: Mutations at the P1’ position of Notch1 decrease intracellular domain stability rather than cleavage by gamma-secretase. Biochem Biophys Res Commun 2002;299:569–573.
    External Resources
  64. Berezovska O, Jack C, Deng A, Gastineau N, Rebeck GW, Hyman BT: Notch1 and amyloid precursor protein are competitive substrates for presenilin1-dependent gamma-secretase cleavage. J Biol Chem 2001;276:30018–30023.
    External Resources
  65. Lleo A, Berezovska O, Ramdya P, Fukumoto H, Raju S, Shah T, Hyman BT: Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression. J Biol Chem 2003;278:47370–47375.
    External Resources
  66. Fischer DF, van Dijk R, Sluijs JA, Nair SM, Racchi M, Levelt CN, van Leeuwen FW, Hol EM: Activation of the Notch pathway in Down syndrome: cross-talk of Notch and APP. FASEB J 2005;19:1451–1458.
    External Resources
  67. Oh SY, Ellenstein A, Chen CD, Hinman JD, Berg EA, Costello CE, Yamin R, Neve RL, Abraham CR: Amyloid precursor protein interacts with notch receptors. J Neurosci Res 2005;82:32–42.
    External Resources
  68. Fassa A, Mehta P, Efthimiopoulos S: Notch 1 interacts with the amyloid precursor protein in a Numb-independent manner. J Neurosci Res 2005;82:214–224.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Mini Reviews

Received: September 14, 2005
Accepted: December 08, 2005
Published online: May 05, 2006
Issue release date: May 2006

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)

For additional information: https://www.karger.com/NDD

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2005, Vol.2, No. 6

May 2006

Article

Recommend This
TOP